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Use of antioxidants to mitigate oxidative stress during ocular inflammatory diseases has shown therapeutic potential. This work
examines a nanoscale therapeutic modality for the eye on the base of antioxidant enzyme, superoxide dismutase 1 (SOD1), termed
“nanozyme.” The nanozyme is produced by electrostatic coupling of the SOD1 with a cationic block copolymer, poly(L-lysine)-
poly(ethyleneglycol), followed by covalent cross-linking of the complexes with 3,3󸀠-dithiobis(sulfosuccinimidylpropionate) sodium
salt. The ability of SOD1 nanozyme as well as the native SOD1 to reduce inflammatory processes in the eye was examined in
vivo in rabbits with immunogenic uveitis. Results suggested that topical instillations of both enzyme forms demonstrated anti-
inflammatory activity; however, the nanozyme was much more effective compared to the free enzyme in decreasing uveitis
manifestations. In particular, we noted statistically significant differences in such inflammatory signs in the eye as the intensities of
corneal and iris edema, hyperemia of conjunctiva, lens opacity, fibrin clots, and the protein content in aqueous humor. Clinical
findings were confirmed by histological data. Thus, SOD1-containing nanozyme is potentially useful therapeutic agent for the
treatment of ocular inflammatory disorders.
1. Introduction
Uveitis is an inflammatory disease of the uvea, a section of
the eye which consists of the middle pigmented vascular
structures of the eye and includes the iris, ciliary body, and
choroid. Common causes of uveitis include infections, mul-
tisystem disorders such as sarcoidosis and Behçet’s disease
and autoimmune disorders such as rheumatoid arthritis or
ankylosing spondylitis [1–4]. Uveitis is a severe sight threat-
ening disease, frequently leading to vision loss and blindness
with retinal vasculitis, retinal detachment, and glaucoma.
Uveitis accounts for 5–20% of legal blindness in United States
and in Europe, and perhaps as much as 25% of blindness
in the developing world [1]. Severe cases of uveitis need to
be treated aggressively to prevent damage caused by chronic
inflammation. Corticosteroids constitute the first line of
therapy for patients with noninfectious ocular inflammatory
disease. However, as the use of corticosteroids became more
prevalent in treating ocular inflammation, the side effects of
this treatment became more prevalent as well. Another class
of compounds, known as “immunosuppressive drugs,” such
as cyclosporine A, was found to be successful in treating
uveitis. However, such treatment is also complicated by side
effects associated with immunosuppression [5–7]. Patients
who cannot take medications because of the side effects or
patients who are not responsive to the existing medications
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experience unavoidable impaired visual function. Thus, it
is important to investigate alternative approaches for the
treatment of uveitis.
Inflammatory diseases, including ocular ones, are accom-
panied by excessive production of reactive oxygen species
(ROS) and by depletion of endogenous antioxidants. Antiox-
idant enzymes, superoxide dismutase 1 (SOD1, also known
as Cu/Zn SOD), catalase, and glutathione peroxidase are
known to be very effective scavengers of ROS.These enzymes
were shown to be effective in the treatment of various eye
diseases associated with oxidative stress. Thus, SOD1 was
used for the treatment of lens-induced and bovine albumin-
induced uveitis in rabbits [8, 9], as well as for the treatment
of acute corneal inflammation in animals induced by sodium
hydroxide [10, 11]. Both SOD1 and glutathione peroxidase
were employed for the treatment of severe experimental
allergic uveitis induced by retinal S antigen in rats [12], while
poly(ethylene glycol)- (PEG-) modified catalase and PEG-
SOD were employed for the treatment of the same type of
uveitis in guinea pigs [13]. We have shown recently [14] that
SOD1 instillations may help to reduce clinical presentations
of immunogenic uveitis in rabbits.
Eye diseases are most commonly and preferably treated
by topical instillations of eye drops. These formulations
face technical and clinical problems, such as solubility of
the components and instability of drug solutions, limited
efficacy and limited corneal/sclera permeability, and local
and systemic toxicity. Moreover, 2min after instillation the
major part of the topical drug solution is eliminated via the
nasolacrimal drainage system limiting ocular penetration of
the drug to less than 5% of the administered dose [15].
Nanoparticles are colloidal drug carrier systems that can
improve the efficacy of drug delivery into the eye by overcom-
ing corneal/sclera diffusion barrier. Drug loaded polymeric
nanoparticles offer several favorable biological properties,
such as biocompatibility and mucoadhesiveness, enhancing
bioavailability without blurring the vision. The use of drug-
containing nanoparticles can decrease the dose of the drug
and diminish side effects. So, nanoparticles are a promising
drug delivery system, which fulfills the requirements for
ophthalmic application (for reviews, see [16, 17]).
Recently, new formulations of antioxidant enzymes,
SOD1 and catalase, were prepared by electrostatic coupling
of these negatively charged enzymes (pI values are 4.95 and
5.8 for SOD1 and catalase, resp.) with cationic block copoly-
mers, such as methoxy-PEG-block-poly(L-lysine hydrochlo-
ride) block copolymer (PEG-pLL
50
), followed by covalent
cross-linking to stabilize nanoparticles. Catalytic nanopar-
ticles based on polyion complexes of enzymes with block
copolymers of opposite charge were termed “nanozymes”
[18–22]. Spontaneous self-assembly of oppositely charged
proteins and polymers results in stoichiometric complexes
with 100% loading efficiency. These nanozymes were shown
to be prospective agents for the treatment of various diseases
of the central nervous system due to prolonged ability to
scavenge experimentally induced ROS in cultured brain
microvessel endothelial cells and central neurons, increased
stability in both blood and brain, enhanced penetration
through the blood-brain barrier, and, therefore, increased
accumulation in brain tissues, in comparisonwith non-cross-
linked complexes and native enzyme [18, 21, 22].
In the current study, we demonstrate the advantages of
topical instillations of superoxide dismutase 1 in the form
of “nanozyme” in the treatment of ocular inflammation in a
rabbit model of immunogenic uveitis.
2. Methods
2.1. Preparation of and Characteristics of Nanozyme. SOD1
nanozyme was synthesized by self-assembly of recombinant
SOD1 (“Enzyme Technologies”, St. Petersburg, Russia) with
cationic block copolymer, PEG-pLL
50
(MW 13 kDa, poly-
dispersity index 1.09, Alamanda Polymers, Huntsville, AL)
in aqueous solution followed by cross-linking with 3,3󸀠-
dithiobis(sulfosuccinimidylpropionate) (DTSSP) as in [21].
Unreacted cross-linker was desalted using NAP-25 column,
and cross-linked nanozymes were purified using a 100 kDa
MWCO filter. Purified particles were then lyophilized from
0.05M Hepes-buffer, pH 7.5, containing 0.15M NaCl, and
stored at −20∘C. For further experiments, precalculated
quantity of lyophilized nanozyme was dissolved in deion-
ized water and gently vortexed for 2min until sample dis-
solved completely. Intensity-mean z-averaged particle diam-
eter (effective diameter), polydispersity index (PDI), and 𝜁-
potential were measured after filtration via a 0.2 𝜇m filter
using a Zetasizer Nano ZS (Malvern Instruments Ltd., MA).
Aliquots of nanozyme solution required for daily experi-
ments were then frozen and kept at −20∘C.
2.2. Enzyme Activity. SOD1 activity was determined using
SOD1 ability to inhibit autooxidation of quercetin as in [23]
with detection kit (Belarusian State University, Belarus). The
experimental sample in phosphate buffer, pH 7.8, contain-
ing 0.08M EDTA, 0.125% (v/v) TEMED, was mixed with
quercetin solution in DMSO. The absorbance was measured
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quercetin autoxidation by SOD1 in experimental samples was



















) × 100. One unit of SOD1 activity was defined as the
amount of SOD1, which inhibits the quercetin autoxidation
by 50%. The protein content was determined using Micro
BCA Protein Assay Kit (Pierce, Rockford, IL).
2.3. In Vitro Drug Release Study. Onemg of SOD1 nanozyme
was dispersed in 0.5mL of PBS, transferred to 100 kDa
MWCO membrane, and centrifuged for 5min at 1200×g.
Supernatant (about 0.05mL) was diluted by PBS to the
initial volume and centrifuged again.The “filtration-dilution”
procedure was repeated 5 times. SOD1 activity and protein
concentration were measured in the initial nanozyme solu-
tion, in each filtrate, and in the final supernatant. In another
series of experiments, equal amounts of freshly dissolved
nanozyme in PBS were incubated at room temperature for
different time periods. Then, the solutions were filtered
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through 100 kDamembrane, and SOD1 activity in the filtrates
was determined.
2.4. Animals. A randomized and double-blinded study was
conducted using adult Chinchilla rabbits weighing 2.0–
2.5 kg. All experiments with live rabbits were carried out
in strict accordance with the Association for Research in
Vision and Ophthalmology (ARVO) statement for the Use of
Animals in Ophthalmic and Vision Research. The protocol
was approved by the Committee on the Ethics of Animal
Experiments of the Helmholtz Institute for Eye Disease
(Permit number 22/2). All efforts were made to minimize
rabbits suffering. After the end of experiments the rabbits
were sacrificed by lethal pentobarbital injection.
2.5. In Vivo Studies. Immunogenic uveitis was induced as
described in [24]. Briefly, rabbits were initially injected
subcutaneously with 5mL of normal horse serum for sensiti-
zation. Ten days later, 5% anesthetic Alcain (Alcon, Belgium)
was instilled into each eye before the intravitreal injections of
70 𝜇L of the same serum in the eyes to induce acute uveitis.
Rabbits received 30 𝜇L of the drug solutions as eye drops
topically in each eye three times a day for 14 days. Three
independent series of experiments for clinical estimation
of uveitis were performed. In each series, animals were
randomly divided into 4 groups (𝑛 = 5 per each group, i.e.,
10 eyes) and treated as follows: (1) control (healthy) group
without uveitis and (2) placebo group with uveitis received
10mM Hepes buffer, pH 7.4, containing 0.15M NaCl; (3)
SOD1 group with uveitis received 1mg/mL SOD1 solution
in the same buffer; (4) treatment (nanozyme) group with
uveitis received 8–10mg/mL SOD1 nanozyme solution in the
same buffer. Hepes buffer did not cause any irritation of the
eye. SOD1 dose was chosen in accordance with what was
recommended in [25]. The dose of nanozyme solution was
calculated based on enzymatic activity of nanozyme (units
permg) so that the activities of SOD1 andnanozyme solutions
were equal; that is, 8–10mg nanozyme corresponded to 1mg
SOD1 by specific activity. Eyes were examined in a double-
blinded trial by indirect ophthalmoscopy using a slit lamp
(Zeiss slit lamp 30SL, USA). Clinical symptoms of uveitis,
including eyelid and conjunctival edema and hyperemia,
corneal edema and neovascularization, iris edema and hyper-
emia, fibrin clots and precipitates on the iris and on the
lens, lens opacity, presence of synechiae (cohesions between
the pupillary margin of iris and anterior part of the lens),
which lead to immobilization of the pupil, and presence of
purulent exudate (hypopyon) and blood (hyphema) in the
anterior chamber of the eye, were estimated. Evaluation of
inflammation scores was performed using a conventional
scale: (0) no symptom; (1) low degree of manifestation; (2)
medium; (3) strong.
2.6. Analyses of Aqueous Humor. Aqueous humor (intraocu-
lar fluid) from anterior chamber of the eye was collected by
paracentesis in limb area under topical anesthesia on day 8
of uveitis (that is, 16 h after last instillations of the drugs) and
on day 4 in the separate experiment on two rabbits (4 eyes)
in each group. The samples were centrifuged at 21,000×g
for 10min, and the supernatant was stored at −20∘C. The
amount of leukocytes was determined microscopically. The
𝛼
2
-macroglobulin content (in arbitrary units) was estimated
indirectly as previously described [26, 27] based on the
ability of the complex of 𝛼
2
-macroglobulin with trypsin to
react with benzoyl-L-arginine-p-nitroanilide as a substrate.





-luminol system as described in
[28] with Trolox, a water-soluble analog of vitamin E, as a
standard antioxidant. Antioxidant activity of the sample was
expressed as trolox-equivalents calculated on the basis of a
trolox standard curve.
2.7. Histopathology. Histopathological analysis was per-
formed in a double-blinded fashion. For this experiment,
we used 10 rabbits (20 eyes), 9 rabbits with uveitis and 1
healthy rabbit. For the topical treatment, rabbits with uveitis
were randomly divided into three groups. The 1st group of 3
rabbits received placebo as described above, the 2nd group of
3 rabbits received native SOD1, and the 3rd group of 3 rabbits
received SOD1 nanozyme with the same SOD1 activity.
On day 4 rabbits were sacrificed by sodium pentobarbital
injection (100mg/kg), and the eyes were enucleated. Samples
were fixed in 10% neutral buffered formalin, dehydrated in
a graded series of alcohol, embedded in paraffin, and cut
into 4-5 𝜇m serial sections. The sections were stained with
haematoxylin and eosin (H&E) and examined in upright
light microscope (Olympus BX51) using dry-air (4./NA0.10;
10./NA0.25; 20./NA0.40) and oil-immersion (100./NA1.25
oil) objectives (Olympus Optical, Tokyo, Japan). Histology
images were recorded in a single-frame mode using a digital
video camera SDU-252 (2048 × 1536, “Spetsteletechnika”,
Russia) integrated into the microscope optical path.
2.8. Statistical Analysis. All data are means ± SEM. Signif-
icance was analyzed using the Mann-Whitney U test with
STATISTICA 6 (StatSoft, Inc., OK).
3. Results
3.1. Synthesis and Characterization of Nanozyme. SOD1
nanozymewas synthesized as described earlier [21] bymixing
of aqueous solutions of SOD1 and block copolymer, PEG-
pLL
50
at pH 7.4 followed by cross-linking and purification.
SOD1 retained 100% its catalytic activity in polyion complex
before cross-linking consistent with previous report [21, 22]
but partly lost activity as a result of cross-linking with DTSSP
and filtering through 100 kDa membrane. Altogether, the
lyophilized dry nanozyme samples displayed the specific
activity about 30 kU/mg, while the activity of the unmodified
pure recombinant SOD1 was ca. 250 kU/mg. The observed
decrease in the specific activity was mainly due to the
presence of the bulk of polymer in nanozyme as well as
to the presence of buffer substance and salt in the final
lyophilized preparation. The DLS analysis revealed that the
particles of SOD1 nanozyme had an effective diameter of
35 nm (compared to about 5 nm for native SOD1, as reported
in [21]), narrow particle size distribution (PDI ca. 0.1), and
nearly neutral (zero) 𝜁-potential.
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Figure 1: The release of SOD1 activity and protein upon subsequent dilutions and filtrations of nanozyme. Nanozyme was dissolved in
deionized water and immediately filtered through 100 kDaMWCO filter, supernatant was diluted using PBS to the initial volume and filtered
again. “Dilution-filtration” steps were repeated, and SOD activity (a) and protein content (b) were determined in each filtrate.The experiment
was performed in duplicate.
To examine whether SOD1 can be released from the
nanozyme we determined the activity of SOD1 in the filtrates
and supernatant (1) after repeated centrifugal filtration of
the nanozyme solution using 100 kDa MWCO filters and
(2) after centrifugal filtration of nanozyme aqueous solution
incubated for different periods of time. In the first experi-
ment, the lyophilized nanozyme was dissolved in deionized
water so that the final concentration of NaCl was 0.15M and
immediately filtered through 100 kDa membrane for 5min.
After this first filtration step, about 24% of the protein and
about 27% of SOD1 activity (Figure 1) were found in the
filtrate. Further dilutions of supernatant to the initial volume
and subsequent filtration resulted in additional release of
SOD1 activity and protein from the nanozyme, albeit to
a lesser extent than the initial filtration step, from 2 to
7% of the initial amount. After 5 subsequent dilutions and
filtrations, the nanozyme retained about 55–65% of both
SOD1 activity and protein. It is interesting that the release of
SOD1 from the nanozyme occurs not only after the “dilution-
filtration-dilution” procedures but also upon incubation of its
aqueous solution for various time periods after preparation.
Specifically, freshly prepared solution of 2mg nanozyme in
0.5mL 0.15M NaCl contained about 25 to 30% free SOD1,
while after 2 hr incubation the same solution contained 40%
of the free SOD1, and 4 hr 40 to 50% of the free SOD1. Further
incubation of the nanozyme solution did not result in the
further release of the free SOD1. These data suggest that the
nanozyme synthesis process and specific chemistries used
in this work produce nanozymes encapsulating significant
portion of SOD1 that is not chemically coupled to the block
copolymer and can be released in the surrounding media as
it was observed previously [22].
3.2. Effects of Topical Instillations of SOD1 and SOD1
Nanozyme on Clinical Manifestations of Immunogenic Uveitis
in Rabbits. We induced immunogenic uveitis in rabbits in
three independent series of experiments. In one series, the
uveitis appeared to show severe manifestations of inflam-
mation in the outer part of the eye (eyelid, cornea, and
conjunctiva), while, in the other two, inflammation of these
tissues was rather moderate. Manifestations of inflammation
in the inner part of the anterior segment of the eye, however,
were significant in all three series of experiments. It is
noteworthy that, in all series, uveitis developed similarly, with
the most acute phase on days 3–5 and fading till the end of
second week.
3.2.1. Rabbits without Treatment (Placebo). Three days past
intravitreal injection of horse serum, the eyes of animals
showed classical clinical symptoms of anterior uveitis which
intensified on day 4. Edema of the eyelid, cornea, and
conjunctiva were observed. Hyperemia of conjunctiva was
significant. Iris had both edema and hyperemia; its structure
was changed.Therewas a lot of fibrin clots in the anterior part
of the eye, which, in several cases, formed massive clouds. In
most eyes, there were multiple synechiae, which resulted in
pupil immobilization, improper pupil form, and the lack of
reaction of pupil to light. Fibrin clots were also found on the
surface of lens of all eyes; lenses itself were characterized by
significant opacity, which thwartedmicroscopic investigation
of the vitreous body. Many animals (about half) had mas-
sive purulent exudates (so-called hypopyon) in the anterior
camera of the eye, which was formed by leukocytes and
detritus. Neovascularization of the cornea, which is known
to be a result of oxidative stress [29], was observed in half























Figure 2:The effect of instillations of nanozyme and SOD solutions
in the rabbit eye on conjunctival hyperemia at uveitis. The data
from three series of experiments were analyzed, each experiment
including 5 animals (10 eyes) in each group: control, placebo, SOD1-
treated, and SOD1 nanozyme-treated group. Thus, 𝑛 = 30 for
each group. The scores were estimated as a degree of manifestation
of hyperemia of conjunctiva: 0: no symptom; 1: low degree of
manifestation; 2: medium degree; 3: strong degree. Symbols: ∗: the
level of significance of differences by the Mann-Whitney U test
𝑝 < 0.05; ∗∗: the level of significance of differences by the Mann-
Whitney U test 𝑝 < 0.01; NS: not significant differences.
of the eyes. Some animals exhibited symptoms of elevated
intraocular blood pressure (from 8th day) which indicated
the development of common uveitis complication, secondary
glaucoma.
3.2.2. SOD1-Treated Rabbits. The development of uveitis in
this group remarkably differed from that in placebo group.
Eyelid edema was much less pronounced, and hypopyon
was absent at all times during the disease. Corneal and
iris edema were only local and diminished in time. Con-
junctival edema and hyperemia were less pronounced as
well. Neovascularization of the cornea in the acute phase of
uveitis was observed in 20–30% of eyes. During treatment,
we observed regress of synechiae formation (from day 4 to
day 8) and partial restoration of the reaction of the pupil
to light. At the end of the treatment, however, lens opacity
decreased insignificantly. Many eyes retained precipitates on
the lens. Figures 2 and 3 are representative examples of the
comparative effects of SOD1 and placebo instillations in the
rabbit eye on conjunctival hyperemia and formation of fibrin
clots at different times during uveitis. It was seen that while
there was no statistical difference between the extents of
hyperemia of conjunctiva in the eyes of SOD-treated and






















Figure 3:The effect of instillations of nanozyme and SOD solutions
in the rabbit eye on the formation of fibrin clots at uveitis. The data
from three series of experiments were analyzed, each experiment
including 5 animals (10 eyes) in each group: control, placebo, SOD1-
treated, and SOD1 nanozyme-treated group. Thus, 𝑛 = 30 for each
group.The scores were estimated as degree of fibrin clots formation:
0: no clots; 1: low degree of clot formation; 2: medium degree; 3:
strong degree. Symbols: ∗: the level of significance of differences by
the Mann-Whitney U test 𝑝 < 0.05; ∗∗: the level of significance
of differences by the Mann-Whitney U test 𝑝 < 0.01; NS: not
significant differences.
placebo-treated eyes on day 3, later (on days 4 and 5) this
difference became statistically significant and on day 8 this
difference is remarkable (Figure 2). On the contrary, there
was no difference between the amount of fibrin clots observed
in SOD-treated and placebo-treated rabbits (Figure 3).
3.2.3. SOD1 Nanozyme-Treated Rabbits. Clinical manifesta-
tions of uveitis in this group were less pronounced and
appeared later than that in placebo- and SOD1-treated
groups. Most importantly, hyperemia of conjunctiva, corneal
edema, iris edema, and lens opacity were significantly less
pronounced than in the two other groups. There were no
eyes with neovascularization of the cornea in this group.
Synechiae were lower by 20–25%, which improved the pupil
reaction to light. Fibrin clots were less intense aswell. Figure 2
demonstrates the effect of SOD1 nanozyme instillations on
the conjunctival hyperemia in comparison with the effects of
instillations of placebo and native SOD1. There was a clear
statistical difference (𝑝 < 0.01) between SOD1 nanozyme
and placebo groups at all times of the disease. Moreover,
nanozyme was statistically more effective than native SOD1
on day 3 (in acute phase of uveitis). The formation of fibrin
clots in the case of nanozyme-treated groups was statistically
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Table 1: Biochemical parameters of aqueous humor on day 8 of uveitis in rabbits.
Biochemical parameter Treatment
Control Placebo SOD1 Nanozyme
Total protein concentration, mg/mL 2.2 ± 0.3 19.3 ± 3.2 15.6 ± 2.3 10.5 ± 1.1∗∗
𝛼
2
-Macroglobulin, arb. U/mL 0.6 ± 0.1 10.8 ± 1.0 8.7 ± 1.5 7.2 ± 1.6∗
Antioxidant activity, U/mL 14.4 ± 1.0 2.3 ± 0.9 3.3 ± 0.6 3.7 ± 0.2
SOD1 activity, trolox-equivalents/mL 280 ± 40 460 ± 100 370 ± 80 330 ± 50∗
∗Significant difference between nanozyme and placebo by the Mann-Whitney U test, 𝑝 < 0.05; ∗∗Significant difference between nanozyme and placebo, and
nanozyme and native SOD1 by the Mann-Whitney U test, 𝑝 < 0.01.
less pronounced (Figure 3) than in the placebo- and SOD1-
treated groups at every time point of uveitis, starting fromday
4. Thus, we demonstrated that nanozyme treatment resulted
in the considerable improvement of uveitis condition in
rabbits compared not only with the untreated animals but
with the native SOD1-treated group as well.
3.3. Effects of Topical Instillations of SOD1 and SOD1
Nanozyme on Clinical Symptoms of Uveitis in the Acute Phase
of the Disease. Most clearly, the differences in the effects of
topical instillations of SOD1 nanozyme, SOD1, and placebo
are seen in the acute phase of the disease, that is, on days
3-4. We compared the efficacy of these treatments using the
sums of the scores for the manifestations of inflammation in
the outer and inner parts of the anterior eye segment. This is
a common approach in ophthalmology to test drug efficacy
[30]. The manifestations of inflammation were assessed by
(1) the eyelid edema, corneal edema, and hyperemia of
conjunctiva in the outer part and (2) the iris edema, lens
opacity, and fibrin clots in the inner part. The results are
shown in Figures 4 and 5. While native SOD1 seems to have
a healing effect on inflammation in the outer part of the
eye, this effect was not statistically significant. In contrast,
SOD1 nanozyme showed statistically significant healing effect
(Figure 4) in comparison with both placebo (𝑝 < 0.01)
and native SOD1 (𝑝 < 0.05). The difference between SOD1
formats was even more pronounced when we compared
their effect on the inflammation in the inner part of the
anterior segment of the eye (Figure 5). While the healing
effect of native SOD1 was not statistically different from that
of placebo, the SOD1 nanozyme showed remarkable healing
effect, which was significantly distinct from the effects of
native SOD1 and placebo (𝑝 < 0.01 in both cases).
3.4. Effect of Treatments on the Leukocyte Counts and Bio-
chemical Parameter of the Aqueous Humor of the Eye. ROS
metabolites are predominantly produced by polymorphonu-
clear leukocytes, which migrate to inflamed tissues and can
serve as an indication of the inflammation. The aqueous
humors from the eyes of all rabbits with uveitis contained
considerable amount of leukocytes both in the acute (day 4)
and later (day 8, e.g., after 16 h after the last instillations of
the drugs) phases of the disease. On day 4, the SOD1-treated
group displayed approximately the same leukocyte counts
as placebo group, while SOD1 nanozyme-treated group


















Figure 4: Comparison of the clinical symptoms of uveitis in external
rabbit eye structures as a sum of the scores for eyelid edema,
conjunctival hyperemia, and corneal edema in the acute phase
of the uveitis. The data from three series of experiments were
analyzed, each experiment including 5 animals (10 eyes) in each
group: control, placebo, SOD1-treated, and SOD1 nanozyme-treated
group. Thus, 𝑛 = 30 for each group. The scores were estimated
as degrees of manifestations of clinical symptoms of the disease: 0:
no symptom; 1: low degree of manifestation; 2: medium degree; 3:
strong degree. Symbols: ∗: the level of significance of differences by
the Mann-Whitney U test 𝑝 < 0.05; ∗∗: the level of significance
of differences by the Mann-Whitney U test 𝑝 < 0.01; NS: not
significant differences.
insignificant. On day 8, both SOD-treated groups showed
the decrease in leukocyte counts, SOD1 nanozyme-treated
group exhibiting statistically significant effect compared with
placebo (Figure 6).
Tissue inflammation is characterized by elevated total
protein concentration in biological fluids along with the
increase in proteinase inhibitor 𝛼
2
-macroglobulin and
decrease of overall antioxidant activity, as well as increase
in endogenous SOD1 [31–34]. Therefore, we determined
these biochemical parameters in aqueous humor on day 8
after the disease onset (Table 1). The protein concentration



















Figure 5: Comparison of the clinical symptoms of uveitis in internal
rabbit eye structures as a sumof the scores for iris edema, fibrin clots,
and lens opacity in the acute phase of the uveitis.The data from three
series of experiments were analyzed, each experiment including 5
animals (10 eyes) in each group: control, placebo, SOD1-treated, and
SOD1 nanozyme-treated group. Thus, 𝑛 = 30 for each group. The
scores were estimated as in the legend of Figure 3. Symbols: ∗∗: the
level of significance of differences by the Mann-Whitney U test 𝑝 <
0.01; NS: not significant differences.



























Figure 6: Leukocyte numbers in aqueous humor of the eye of uveitis
rabbits as percentage from the value for control (healthy) rabbits on
different times of the disease. 𝑛 = 4 in each group on day 8; 𝑛 = 10
in each group on day 8.
in nontreated group increased 8-fold compared to healthy
animals and it was only slightly affected after the native
SOD1 treatment. In contrast, SOD1 nanozyme treatment
resulted in nearly 2-fold decrease in this parameter. The
effect of nanozyme was significant compared to both
placebo and native SOD1 (𝑝 < 0.01). The development of
uveitis also resulted in drastic increase of 𝛼
2
-macroglobulin
activity in aqueous humor; however it was mitigated after
both the native SOD1 and, especially, SOD1 nanozyme
treatments (Table 1). Antioxidant activity increase in both
SOD1 and nanozyme-treated groups was rather small and
not significant (Table 1). The endogeneous SOD1 activity
in aqueous humor of placebo-treated eyes with uveitis was
increased by more than in 1.5 times compared to control
group suggesting a compensatory reaction of the eye to the
uveitis-induced oxidative stress. The native SOD1 treatments
decreased the enzyme activity in aqueous humor, albeit
nonsignificant, while SOD1 nanozyme treatment decreased
this parameter significantly (Table 1). Notably, in the healthy
and placebo-treated rabbits, SOD1 activity in aqueous humor
represents only the endogenous enzyme, while in SOD1- and
nanozyme-treated rabbits it may contain contributions of
exogenous SOD1 as well. Still the decrease in the measured
SOD1 activity in treated eyes clearly shows that SOD1 and,
especially, nanozyme treatments decrease inflammation
during experimental uveitis.
3.5. Histology Examination of the Disease Manifestation. The
eyes of the control, healthy rabbits were unchanged. The
cornea displayed its common structure with thin multilayer
epithelium on the outer side (cells form 2 or 3 layers) and
single-layer endothelium on the inner side (Figure 7(a)).
The epithelium and endothelium cells had normal structure;
the main part of the stroma could be clearly seen. The
conjunctival tissue was loose, moderately full-blooded. The
vessels in the region of conjunction of cornea, conjunctiva,
and sclera were wide and full-blooded as well. The sclera and
ciliary body (Figure 8(a)) possessed their normal structure
as well. The retina in the eyes of normal rabbits was also
unchanged.
3.5.1. Rabbits without Treatment (Placebo). In the placebo
group having uveitis, one eye contained white, thick, non-
transparent expandingmass.Thismass is known to represent
a purulent exudate, consisting of leukocytes (some of them
in a stage of disintegration) and small amount of fibrin. The
vitreous body in this eye was in the state of destruction and
cell infiltration. Another eye of the same animal, as well
as the eyes of other rabbits in this group, maintained the
vitreous body but the inner part of choroid contained white
precipitates. Choroid in these eyes was thickened, known
to be due to infiltration of neutrophils, macrophages, and
lymphocytes. Some destruction of the pigment cells layer
was also observed. The vessels within choroid were full-
blooded but with some extent of erythrocyte aggregation.
The cornea in this group exhibited edema, swelling, and
loosening of collagen fibers, aswell as partial desquamation of
endothelium and partial destruction of Descemet membrane
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Figure 7: Histology picture of the cornea, stained with hematoxylin and eosin, magnification ×200, on day 4 of uveitis. (a) Control (𝑛 = 2):
cornea is lined with epithelium and endothelium; collagen fibers and keratocytes (specialized corneal fibroblasts) are visible; (b) placebo
(𝑛 = 6): swelling and loosening of corneal collagen fibers, endothelial desquamation, partial destruction of Descemet’s membrane; epithelium
is not changed; (c) SOD1 (𝑛 = 6):moderate loosening of the corneal collagen fibers, partial endothelial desquamation, cell infiltration is absent;
(d) SOD1 nanozyme (𝑛 = 6): normal structure of the cornea.
(Figure 7(b)). Epithelium of the cornea was not changed.The
sclera in almost all eyes exhibited pronounced edema and
contained sporadic neutrophil-macrophage infiltrates. The
bundles of collagen fibers within sclera were loosened. There
were also significant edema and inflammatory infiltration in
ciliary body (Figure 8(b)), while loosened stroma of ciliary
body exhibited signs of cellular dystrophy, characterized by
the formation of cytoplasm vacuoles. Partial destruction and
desquamation of epithelium of ciliary body and its processes
with deposits of purulent exudates was also observed. Retina
in the eyes of rabbits from this group had regions of
destruction and exhibited signs of dystrophy of cells elements.
3.5.2. SOD1-Treated Rabbits. The eyes of rabbits in the SOD1
treatment group had only moderate inflammation manifes-
tation in uveal tract. The cornea was lined by unchanged
epithelium. The Descemet membrane did not have defects;
however, some regions of the cornea contained loosened col-
lagen fibrils, and the endothelium was partially desquamated
(Figure 7(c)). The sclera exhibited moderate edema and
looseness with some inflammatory infiltration. The choroid
was relatively thin, without purulent exudates but with slight
infiltration by neutrophils, lymphocytes, and macrophages.
Some eyes, however, contained thickened regions of choroid
with more pronounced infiltrates, especially in the posterior
segment of the eye. The ciliary body retained its ordinary
structure, but exhibited some regions of edema and inflam-
matory cell infiltration (Figure 8(c)).
3.5.3. SOD1 Nanozyme-Treated Rabbits. In the SOD1 nanoz-
yme-treated group, 2 eyes (from 6 eyes examined) hardly
showed any inflammatory symptoms.These eyes appeared to
be unaffected by the disease and were indistinguishable of the
eyes of the healthy rabbits. In the remaining eyes the cornea
was laid by epithelium and endothelium without desquama-
tion; the collagen fibers and keratocytes of stroma showed
no changes as well (Figure 7(d)). The sclera in the eyes of
this group was of common thickness without inflammation
and loosening.The choroid was thin without destruction and
cell infiltration. The retina was also unchanged. The ciliary
body also displayed its natural structure, without signs of
infiltration (Figure 8(d)).
Thus, while native SOD1 showed a pronounced thera-
peutic effect in the treatment of experimental immunogenic
uveitis in rabbits, the nanoformulated form, SOD1 nanozyme,
provided much more remarkable effect as revealed by the
histopathology analysis.
4. Discussion
ROS are excessively produced in many disease states
and contribute to tissue degeneration and pathogenesis of
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Figure 8: Histological picture of the ciliary body, stained with hematoxylin and eosin, magnification ×200, on day 4 of uveitis. (a) Control
(𝑛 = 2): ciliary body with processes, moderate plethora; (b) placebo (𝑛 = 6): edema and infiltration of the ciliary body, deposition of purulent
exudates; (c) SOD1 (𝑛 = 6): edema and inflammatory infiltration of the ciliary body; (d) SOD1 nanozyme (𝑛 = 6): ciliary body without cellular
infiltration.
many clinical conditions including atherosclerosis, stroke,
ischemia/reperfusion injury, myocardial infarction, central
nervous system disorders, and wounds. In particular, ROS
metabolites may be important factors in the early tissue dam-
age that develops from immunopathologic inflammations
[35–37]. Uncontrolled ROS production in acute inflamma-
tion can lead to destruction of structural and functional
proteins as well as lipids in cell membranes. Because of the
nonspecific nature of ROS-induced tissue injury, excessive
release of these agents can cause substantial damage not only
to the tissue in an inflamed state but also to the surrounding
normal tissue. In particular, this is very important for the
eye, as the transparency of the cornea and lens, as well as
the functioning of photoreceptor apparatus, relies on their
highly ordered structures, and excessive tissue damage will
compromise visual function.
Antioxidants, SOD1 in particular, are known to be ben-
eficial in the treatment of the various diseases connected
with oxidative stress. Thus, SOD1 was reported to reduce
inflammation [38], accelerate the healing of skin lesions
caused by burns, systemic lupus erythematosus, and herpes
[39–41], protect cultured human neurons under oxidative
stress [42], reduce ischemia-reperfusion injury [22, 43, 44],
inhibit angiotensin II (AngII) intraneuronal signaling [19],
prolong viability of 𝛽-cells [45], be effective in the treatment
of rat adjuvant arthritis [46], and so forth. Most relevant
to this study, antioxidants, including SOD, are also thought
to be beneficial in the treatment of eye diseases. The eye
is rather isolated organ, and the pathological processes
within it are preferably treated not via systemic but by local
drug intake. SOD1 was found in the corneas of mammals
[47], suggesting that the enzyme plays an important role in
maintaining homeostasis of the ocular surface. The use of
topical, subconjunctival, parabulbar, or intraocular injections
of SOD1 could, therefore, provide a supplement for intrinsic
antioxidants in eye tissues, which may be depleted during
inflammation.
According to official statistics, inflammatory eye dis-
eases are the most common eye pathologies which lead
to partial disability and, sometimes, to the complete loss
of vision. Among these diseases, the most severe one is
uveitis, inflammation of uveal tract involving both outer
and inner structures of the eye. Both noninfectious and
infectious uveitis are accompanied by the enhancement of
free radicals formation and by the increase of the content of
the products of lipid oxidation in eye tissues. The major role
in ROS formation in the eye belongs to polymorphonuclear
leukocytes, which initiate as well as perpetuate themembrane
oxidative processes at uveitis. Thus uveitis is believed to
be strongly associated with overproduction of ROS in the
eye tissues during inflammation, and antioxidants can play
beneficial role in the treatment of this disease [48]. It was
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shown [9] that superoxide production by the leukocytes of
Behçet patients (with uveal inflammation) was significantly
higher in the attack phase than in the remission phase. Leuko-
cyte superoxide generation was also enhanced in guinea pigs
with S-antigen-induced experimental autoimmune uveitis.
These observations indicate the perspectives of the use of
antioxidants, SOD1 in particular, as potential drugs in the
treatment of uveitis.
Previous studies have shown beneficial effects of SOD1 in
the treatment of eye inflammation, including uveitis and eye
burns.Thus, animals with phacoanaphylactic endophthalmi-
tis (lens-induced uveitis) were treated with SOD1 [8]. This
treatment resulted in strong reduction of choroid inflamma-
tion, retinal edema, and vasculitis. In another study aqueous
humor cell quantity and infiltration of the inflammatory cells
in the anterior retina weremarkedly reduced in SOD1-treated
animals with both S-antigen induced and bovine serum
albumin-induced passive Arthus type uveitis [9]. Positive
effect of SOD1 was also demonstrated on the rabbit model
of immunogenic uveitis [14]. Moreover, topical antioxidant
therapy by SOD1 in acute corneal inflammation (induced by
alkali burn) was shown to be efficient in reduction of corneal
ulcers [11], while subconjunctival injections of SOD1 were
reported to prevent tissue destruction after alkali burns of the
eye and prevented corneal perforation [10].
However, the methods of the treatment of the diseases,
which include inner structures of the eye, are relatively less
effective due to the poor transport of proteins and other
drugs into the eye. In recent years, there has been significant
interest in the developing nanosized drug delivery systems
to overcome the limitations of drug therapy. Such nanosys-
tems can improve the therapeutic efficacy of the drugs by
overcoming diffusion barrier, by increasing their stability in
biological tissues and fluids and enhancing cellular/tissue
uptake. These nanosystems are attractive for the treatment
of various eye diseases, including both acute and chronic
conditions [17, 49]. So far, SOD1 entrapped in liposomes
was previously shown to be effective in the treatment of
noninfectious corneal ulcers [50].
Recently, a cross-linked polyion complex of SOD1 with
a cationic block copolymer PEG-pLL
50
, termed “SOD1
nanozyme,” was developed [21, 22].This SOD1 nanoformat is
characterized by high dispersion stability, small particle size,
particle uniformity, decreased cellular toxicity, and efficient
transport into cells. SOD1-nanozyme was shown to be able to
effectively scavenge ROS and decrease ischemia/reperfusion-
induced tissue injury and improve sensorimotor functions
in a rat middle cerebral artery occlusion model [22]. In
this study, the therapeutic efficacy of SOD1 nanozyme for
the treatment of ophthalmic inflammatory diseases was
demonstrated in a rabbit model of immunogenic uveitis.
Immunogenic uveitis is an animal model of acute ocular
inflammation induced by the intraocular injection of serum
from a foreign animal after presensitization. This type of
uveitis usually includes inflammation in the anterior, inter-
mediate, and posterior segments of the eye, thus representing
panuveitis. We hypothesized that antioxidant agent SOD1
in the form of nanozyme can attenuate oxidative stress and
produce a significant therapeutic effect. For the treatment, we
have chosen the most simple and convenient drug formula-
tion, aqueous solution of nanozyme as eye drops.
In this study, wemostly followed clinical and biochemical
parameters in the anterior segment of the eye in uveitis,
while further histological study allowed us to estimate uveitis
manifestations in the posterior segment of the eye as well.
Clinical manifestations of uveitis in the anterior segment of
the eye could be divided into two groups. The first are man-
ifestations in the outer part of the segment including eyelid
edema, eyelid hyperemia, conjunctival edema, conjunctival
hyperemia, corneal edema, and neovascularization of the
cornea. The second are manifestations in the inner part of
the segment including iris edema, iris hyperemia, fibrin clots
and precipitates on the iris and on the lens, lens opacity, the
existence of synechiae, and the existence of exudates in the
anterior chamber of the eye.
The major result of this study is a clear demonstration
that topical instillations of SOD1 nanozyme solution into the
eye exhibit remarkable effect on the clinical manifestation
of the disease, improve biochemical characteristics of the
aqueous humor, and help to maintain the cells of various
eye tissues in normal condition. In the eyes of rabbits not
receiving any treatment, but receiving placebo instead, we
observed acute panuveitis. Inflammation included entire
uveal tract, which, in turn, caused inflammation in other eye
tissues. Deformation of almost every eye tissue was observed,
retina (defects of photoreception apparatus), ciliary body
(distortion in the aqueous humor formation and in accom-
modation), iris (changes in the structure and immobilization
of the pupil), lens (opacity, cataract), and cornea (decrease of
the transparency). In the second group of rabbits receiving
native SOD1 solution, the clinical manifestations of uveitis
were less severe. However, edema, inflammatory infiltration,
and endothelium desquamation were still observed. In the
third group of rabbits receiving SOD1 nanozyme solution
the therapeutic effect of antioxidant agent was much more
pronounced. We observed statistically significant differences
in those clinical manifestations of uveitis, such as corneal
and iris edema, hyperemia of conjunctiva, lens opacity, and
amount of fibrin clots between this group and native SOD1-
treated group.The biochemical characteristics of the aqueous
humor were also improved. Moreover, histological study
demonstrated almost normal structure of eye tissues from
this group. Remarkably, the proposed therapy appears to be
beneficial for treatment of not only the surface but also inner
areas of the eye.
The current study did not allow precise delineating of the
mechanism by which the nanozyme formulation improves
the therapeutic effect of SOD1. The effect of the topical
application of common drugs is greatly impeded by the
protective physiological barriers of the eye, which effectively
decrease the concentration of the drug in the site of the
action [15]. Previous works have shown that incorporation of
SOD1 in nanozyme format increases the efficacy of nanozyme
delivery in cells [19, 51]. Moreover, the stability of the enzyme
taken up into the cells within the nanozyme format is greatly
increased, presumably, due to stabilization of the enzyme
molecule against metabolic degradation and/or lysosomal
escape [22]. Studies have also shown that nanozymes can
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be taken up in macrophages, when they can reside for
considerable periods of time [18, 20]. Nanozymes can be
also transported with macrophages to distal disease sites,
where they are released into the extracellular media as well
as within other tissue cells and exerted the protective effect
by scavenging the ROS [52, 53]. All these effects could in
principle contribute to improved therapeutic effect of the
SOD1 nanozyme during uveitis observed in this work.
Altogether the results obtained demonstrate high poten-
tial therapeutic efficacy of topical administration of SOD1
nanozyme for the treatment of inflammatory eye diseases.
Most current therapies of uveitis are predominantly based on
steroids and immunosuppressants [54, 55]. However, steroids
have systemic side effects such as cataract, glaucoma, and
secondary ocular hypertension [56, 57], while immunosup-
pressive drugs are teratogenic and contraindicated during
pregnancy [55]. Intraocular or periocular injections can
deliver relatively high doses of drug to the eye with fewer
side effects [54, 55]; however, each such injection is in essence
a minor surgical procedure that could be quite disruptive
and inconvenient to a patient. Recently, several sustained-
release drug delivery implants have been developed to treat
noninfectious uveitis, but such implantation requires surgical
operation and the cost of this invasive treatment is high to the
patients and insurance companies [55].
Therefore a noninvasive topical SOD1 nanoformat that
can be conveniently applied as eye drops by a patient if
shown successful as a therapeutic modality could be a major
breakthrough in treatment of uveitis and possibly other
inflammatory conditions of the eye.
5. Conclusions
In summary our work demonstrates that the nanozyme
formed by self-assembly of the SOD1 with PEG-pLL
50
block
copolymer and stabilized by cross-linking can be used as a
carrier for sustained delivery of SOD1 into ocular tissues for
the treatment of inflammation processes in the eye. Topi-
cal instillations of SOD1-nanozyme significantly decreased
inflammation both in the outer and inner parts of the eye
as determined using scores of the clinical manifestations of
uveitis, multiple biochemical parameters, and histological
analysis. These results may have broad clinical implications
in the treatment of other disorders of the eye where oxidative
stress contributes to pathology.
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